Showcasing data on our oncolytic viral therapy at AACR 2025
We showcase breakthrough data on our engineered oncolytic viral therapy, a first-in-class for pediatric liver cancer
We are excited to share that Humane Genomics is returning to the American Association for Cancer Research (AACR) annual meeting for the third time! With over 23,000 attendees (in 2024), AACR is the largest gathering of cancer researchers, clinicians, survivors, and advocates in the world. It is an honor to be invited back to this prestigious event where we will be showcasing our groundbreaking work in the field of cancer therapeutics.
Where to find us
Session: Oncolytic Viruses 1
Poster Board: 25
Date & Time: Sunday, April 27, 2025 | 2:00 PM – 5:00 PM CT
Location: AACR 2025, McCormick Place Convention Center, Chicago, IL
Our poster highlights preclinical findings from our lead candidate, HGI627, an engineered oncolytic vesicular stomatitis virus (VSV) therapy. It is titled: “Novel Oncolytic Virus Targeting GPC3 and CTNNB1 Demonstrates Complete Response in Hepatocellular Carcinoma (HCC) Xenograft with a Single, Systemic Administration”. You can view the full abstract here: AACR Presentation #946.
Childhood liver cancers have limited treatment options
Childhood liver cancers like hepatoblastoma and pediatric HCC still carry dismal prognoses and limited treatment options. At Humane Genomics, we have developed our platform to engineer highly targeted viral therapies with excellent efficacy. HGI627 is a product of this platform—designed with two-factor authentication:
- A retargeted glycoprotein for tumor-specific infection targeting GPC3, and
- A replication ON-switch responsive to CTNNB1, a frequently dysregulated oncogene in liver cancer.
Our poster presents the latest in vivo findings
- Complete response in Hep3B xenografts following a single IP dose of HGI627
- >99.9% tumor reduction, with residual cells confirmed apoptotic
- Excellent tolerability even at doses 300x higher than anticipated clinical starting dose
Let’s connect
We are eager to meet with clinicians, scientists, and partners who share our vision for the future of cancer therapy. If you will be at AACR 2025 and are interested in synthetic virology, liver cancer, or selective drug delivery—we would love to connect. Our platform enables rapid development of potent, targeted oncolytic viruses against new receptors and protein targets, making it highly adaptable across cancer indications, so we are also happy to discuss development of new therapies for other cancers too.
Swing by our poster, or leave a comment here, we will get back to you.
See you in Chicago!